O	0	7	Overall
O	8	16	survival
O	17	24	results
O	25	29	from
O	30	33	the
O	34	44	randomized
O	45	50	phase
O	51	52	2
O	53	58	study
O	59	61	of
B-intervention	62	73	palbociclib
I-intervention	74	76	in
I-intervention	77	88	combination
I-intervention	89	93	with
I-intervention	94	103	letrozole
O	104	110	versus
B-control	111	120	letrozole
I-control	121	126	alone
O	127	130	for
O	131	136	first
O	136	137	-
O	137	141	line
O	142	151	treatment
O	152	154	of
O	155	157	ER
O	157	158	+
O	158	159	/
O	159	163	HER2
O	163	164	-
O	165	173	advanced
O	174	180	breast
O	181	187	cancer
O	188	189	(
O	189	195	PALOMA
O	195	196	-
O	196	197	1
O	197	198	,
O	199	203	TRIO
O	203	204	-
O	204	206	18
O	206	207	)
O	207	208	.

O	209	220	Palbociclib
O	221	223	is
O	224	225	a
O	226	232	cyclin
O	232	233	-
O	233	242	dependent
O	243	249	kinase
O	250	251	4
O	251	252	/
O	252	253	6
O	254	255	(
O	255	259	CDK4
O	259	260	/
O	260	261	6
O	261	262	)
O	263	272	inhibitor
O	272	273	,
O	274	282	approved
O	283	285	in
O	286	297	combination
O	298	302	with
O	303	312	endocrine
O	313	320	therapy
O	321	324	for
O	325	328	the
O	329	338	treatment
O	339	341	of
O	342	347	women
O	348	351	and
O	352	355	men
O	356	360	with
O	361	368	hormone
O	369	377	receptor
O	377	378	-
O	378	386	positive
O	386	387	,
O	388	393	human
O	394	403	epidermal
O	404	410	growth
O	411	417	factor
O	418	426	receptor
O	427	428	2
O	428	429	-
O	429	437	negative
O	438	446	advanced
O	447	453	breast
O	454	460	cancer
O	461	462	(
O	462	464	HR
O	464	465	+
O	465	466	/
O	466	470	HER2
O	470	471	-
O	472	475	ABC
O	475	476	)
O	476	477	.

O	478	480	In
O	481	484	the
O	485	490	phase
O	491	492	2
O	492	493	,
O	494	498	open
O	498	499	-
O	499	504	label
O	504	505	,
O	506	512	PALOMA
O	512	513	-
O	513	514	1
O	515	520	trial
O	520	521	,
O	522	533	palbociclib
O	534	538	plus
O	539	548	letrozole
O	549	562	significantly
O	563	572	prolonged
B-outcome	573	584	progression
I-outcome	584	585	-
I-outcome	585	589	free
I-outcome	590	598	survival
I-outcome	599	600	(
I-outcome	600	603	PFS
I-outcome	603	604	)
O	605	611	versus
O	612	621	letrozole
O	622	627	alone
O	628	629	(
O	629	635	hazard
O	636	641	ratio
O	641	642	,
O	643	644	0
O	644	645	.
O	645	648	488
O	648	649	;
O	650	652	95
O	652	653	%
O	654	656	CI
O	657	658	0
O	658	659	.
O	659	662	319
O	662	663	â€’
O	663	664	0
O	664	665	.
O	665	668	748
O	668	669	;
O	670	671	P
O	672	673	=
O	674	675	0
O	675	676	.
O	676	680	0004
O	680	681	;
B-outcome	682	688	median
I-outcome	689	692	PFS
O	692	693	,
B-iv-cont-median	694	696	20
I-iv-cont-median	696	697	.
I-iv-cont-median	697	698	2
O	699	701	vs
B-cv-cont-median	702	704	10
I-cv-cont-median	704	705	.
I-cv-cont-median	705	706	2
I-cv-cont-median	707	713	months
O	713	714	,
O	715	727	respectively
O	727	728	)
O	729	731	in
O	732	746	postmenopausal
O	747	752	women
O	753	757	with
O	758	766	estrogen
O	767	775	receptor
O	775	776	-
O	776	784	positive
O	785	786	(
O	786	788	ER
O	788	789	+
O	789	790	)
O	790	791	/
O	791	795	HER2
O	795	796	-
O	797	800	ABC
O	800	801	.

O	802	806	Here
O	806	807	,
O	808	810	we
O	811	818	present
O	819	822	the
O	823	828	final
O	829	836	overall
O	837	845	survival
O	846	847	(
O	847	849	OS
O	849	850	)
O	851	854	and
O	855	862	updated
O	863	869	safety
O	870	877	results
O	877	878	.

B-eligibility	879	893	Postmenopausal
I-eligibility	894	899	women
I-eligibility	900	904	with
I-eligibility	905	907	ER
I-eligibility	907	908	+
I-eligibility	908	909	/
I-eligibility	909	913	HER2
I-eligibility	913	914	-
I-eligibility	915	918	ABC
O	919	923	were
O	924	934	randomized
O	935	936	1
O	936	937	:
O	937	938	1
O	939	941	to
O	942	949	receive
O	950	956	either
O	957	968	palbociclib
O	969	970	(
O	970	973	125
O	974	976	mg
O	976	977	/
O	977	980	day
O	980	981	,
O	982	983	3
O	983	984	/
O	984	985	1
O	986	994	schedule
O	994	995	)
O	996	1000	plus
O	1001	1010	letrozole
O	1011	1012	(
O	1012	1013	2
O	1013	1014	.
O	1014	1015	5
O	1016	1018	mg
O	1018	1019	/
O	1019	1022	day
O	1022	1023	,
O	1024	1034	continuous
O	1034	1035	)
O	1036	1038	or
O	1039	1048	letrozole
O	1049	1054	alone
O	1055	1056	(
O	1056	1057	2
O	1057	1058	.
O	1058	1059	5
O	1060	1062	mg
O	1062	1063	/
O	1063	1066	day
O	1066	1067	,
O	1068	1078	continuous
O	1078	1079	)
O	1079	1080	.

O	1081	1084	The
O	1085	1092	primary
O	1093	1101	endpoint
O	1102	1105	was
O	1106	1118	investigator
O	1118	1119	-
O	1119	1127	assessed
B-outcome-Measure	1128	1131	PFS
O	1131	1132	;
O	1133	1142	secondary
O	1143	1152	endpoints
O	1153	1161	included
B-outcome-Measure	1162	1164	OS
O	1165	1168	and
B-outcome-Measure	1169	1175	safety
O	1175	1176	.

O	1177	1178	A
O	1179	1184	total
O	1185	1187	of
B-total-participants	1188	1191	165
O	1192	1200	patients
O	1201	1205	were
O	1206	1216	randomized
O	1216	1217	.

O	1218	1220	At
O	1221	1224	the
O	1225	1229	data
O	1230	1236	cutoff
O	1237	1241	date
O	1242	1244	of
O	1245	1253	December
O	1254	1256	30
O	1256	1257	,
O	1258	1262	2016
O	1263	1264	(
O	1264	1270	median
O	1271	1279	duration
O	1280	1282	of
O	1283	1289	follow
O	1289	1290	-
O	1290	1292	up
O	1292	1293	,
O	1294	1296	64
O	1296	1297	.
O	1297	1298	7
O	1299	1305	months
O	1305	1306	)
O	1306	1307	,
O	1308	1311	the
O	1312	1322	stratified
O	1323	1329	hazard
O	1330	1335	ratio
O	1336	1339	for
B-outcome	1340	1342	OS
O	1343	1346	was
O	1347	1348	0
O	1348	1349	.
O	1349	1352	897
O	1353	1354	(
O	1354	1356	95
O	1356	1357	%
O	1358	1360	CI
O	1361	1362	0
O	1362	1363	.
O	1363	1366	623
O	1366	1367	-
O	1367	1368	1
O	1368	1369	.
O	1369	1372	294
O	1372	1373	;
O	1374	1375	P
O	1376	1377	=
O	1378	1379	0
O	1379	1380	.
O	1380	1383	281
O	1383	1384	)
O	1384	1385	;
B-outcome	1386	1392	median
I-outcome	1393	1395	OS
O	1396	1398	in
O	1399	1402	the
O	1403	1414	palbociclib
O	1415	1419	plus
O	1420	1429	letrozole
O	1430	1433	and
O	1434	1443	letrozole
O	1444	1449	alone
O	1450	1454	arms
O	1455	1458	was
B-iv-cont-median	1459	1461	37
I-iv-cont-median	1461	1462	.
I-iv-cont-median	1462	1463	5
O	1464	1467	and
B-cv-cont-median	1468	1470	34
I-cv-cont-median	1470	1471	.
I-cv-cont-median	1471	1472	5
I-cv-cont-median	1473	1479	months
O	1479	1480	,
O	1481	1493	respectively
O	1493	1494	.

O	1495	1498	The
B-outcome	1499	1505	median
I-outcome	1506	1510	time
I-outcome	1511	1515	from
I-outcome	1516	1529	randomization
I-outcome	1530	1532	to
I-outcome	1533	1538	first
I-outcome	1539	1549	subsequent
I-outcome	1550	1562	chemotherapy
I-outcome	1563	1566	use
O	1567	1570	was
O	1571	1577	longer
O	1578	1582	with
O	1583	1594	palbociclib
O	1595	1599	plus
O	1600	1609	letrozole
O	1610	1614	than
O	1615	1624	letrozole
O	1625	1630	alone
O	1631	1632	(
B-iv-cont-median	1632	1634	26
I-iv-cont-median	1634	1635	.
I-iv-cont-median	1635	1636	7
O	1637	1640	and
B-cv-cont-median	1641	1643	17
I-cv-cont-median	1643	1644	.
I-cv-cont-median	1644	1645	7
I-cv-cont-median	1646	1652	months
O	1652	1653	,
O	1654	1666	respectively
O	1666	1667	)
O	1667	1668	.

O	1669	1672	The
O	1673	1677	most
O	1678	1688	frequently
O	1689	1697	reported
O	1698	1705	adverse
O	1706	1711	event
O	1712	1714	in
O	1715	1718	the
O	1719	1730	palbociclib
O	1731	1735	plus
O	1736	1745	letrozole
O	1746	1749	arm
O	1750	1753	was
B-outcome	1754	1765	neutropenia
O	1766	1767	(
B-outcome	1767	1770	any
I-outcome	1771	1776	grade
O	1776	1777	,
B-iv-bin-percent	1778	1780	75
I-iv-bin-percent	1780	1781	%
I-iv-bin-percent	1781	1782	;
B-outcome	1783	1788	grade
I-outcome	1789	1790	3
I-outcome	1791	1793	or
I-outcome	1794	1795	4
O	1795	1796	,
B-iv-bin-percent	1797	1799	59
I-iv-bin-percent	1799	1800	%
O	1800	1801	)
O	1801	1802	.

O	1803	1814	Palbociclib
O	1815	1819	plus
O	1820	1829	letrozole
O	1830	1839	treatment
O	1840	1843	led
O	1844	1846	to
O	1847	1848	a
O	1849	1858	numerical
O	1859	1862	but
O	1863	1866	not
O	1867	1880	statistically
O	1881	1892	significant
O	1893	1904	improvement
O	1905	1907	in
O	1908	1914	median
O	1915	1917	OS
O	1917	1918	.

O	1919	1925	Pfizer
O	1926	1929	Inc
O	1930	1931	(
O	1931	1942	NCT00721409
O	1942	1943	)
O	1943	1944	.
